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Abstract
Background: Host restriction factor APOBEC3G (A3G) blocks human immunodeficiency virus
type 1 (HIV-1) replication by G-to-A hypermutation, and by inhibiting DNA synthesis and provirus
formation. Previous reports have suggested that A3G is a dimer and its virion incorporation is
mediated through interactions with viral or nonviral RNAs and/or HIV-1 Gag. We have now
employed a bimolecular fluorescence complementation assay (BiFC) to analyze the intracellular
A3G-A3G, A3G-RNA, and A3G-Gag interactions in living cells by reconstitution of yellow
fluorescent protein (YFP) from its N- or C-terminal fragments.
Results: The results obtained with catalytic domain 1 and 2 (CD1 and CD2) mutants indicate that
A3G-A3G and A3G-Gag multimerization is dependent on an intact CD1 domain, which is required
for RNA binding. A mutant HIV-1 Gag that exhibits reduced RNA binding also failed to reconstitute
BiFC with wild-type A3G, indicating a requirement for both HIV-1 Gag and A3G to bind to RNA
for their multimerization. Addition of a non-specific RNA binding peptide (P22) to the N-terminus
of a CD1 mutant of A3G restored BiFC and virion incorporation, but failed to inhibit viral
replication, indicating that the mutations in CD1 resulted in additional defects that interfere with
A3G's antiviral activity.
Conclusion: These studies establish a robust BiFC assay for analysis of intracellular interactions
of A3G with other macromolecules. The results indicate that in vivo A3G is a monomer that forms
multimers upon binding to RNA. In addition, we observed weak interactions between wild-type
A3G molecules and RNA binding-defective mutants of A3G, which could explain previously
described protein-protein interactions between purified A3G molecules.
Background
Human immunodeficiency virus type 1 (HIV-1) has
infected over 33 million people in the world, leading to
the AIDS pandemic http://www.who.int. Recent discovery
of intracellular host restriction factors suggests that HIV-1
must overcome these defenses in order to replicate and
cause AIDS [1,2]. A3G, a member of the APOBEC3 family
of proteins, is a host restriction factor that potently inhib-
its the replication of HIV-1 vectors that fail to express a
functional Vif protein [1]. In the absence of Vif, A3G
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deaminates cytidines of the viral minus-strand DNA,
resulting in G-to-A hypermutation of the viral genome;
additionally, A3G inhibits viral DNA synthesis and provi-
rus formation [3-8]. A3G may also inhibit HIV-1 replica-
tion by inducing degradation of the HIV DNA [3]. HIV-1
expresses the Vif protein, which binds to A3G and targets
it for proteasomal degradation [9-14].
A3G and other APOBEC3 proteins contain two catalytic
domains (CD1 and CD2), with the consensus amino acid
sequence H-X-E-X23–28-P-C-X2–4-C [15,16]. The histidine
and cysteine residues coordinate Zn2+, and the glutamic
acid serves as a proton shuttle in the deamination reaction
[15]. Substitutions of the HECC residues in the CD1 or
CD2 catalytic domains and characterization of A3G and
APOBEC3F (A3F) chimeric proteins have shown that cyti-
dine deaminase activity in A3G and A3F is primarily asso-
ciated with CD2 [17]. CD2 also confers the sequence
specificity for A3G cytidine deamination, which is a CC
dinucleotide on the minus-strand DNA (a GG dinucle-
otide on the plus-strand DNA); deamination of a cytidine
in the minus-strand DNA most frequently results in
replacement of the first G with A in the plus-strand DNA
[3,4,6,17]. The CD1 domain of A3G does not possess cyti-
dine deamination activity but has been implicated in RNA
binding and viral encapsidation [17,18]. A3G has been
known to form dimers and multimers [15,18-20]. Like
other members of the cellular deaminase family, A3G
binds RNA in vitro [15,21-24]. Co-immunoprecipitation
(co-IP) of A3G molecules that possess different immuno-
logical tags is dependent on the presence of RNA, suggest-
ing that their multimerization requires RNA binding
[18,22,25]. On the other hand, it has been observed that
when A3G is purified it forms multimers, suggesting that
A3G may form multimers using protein-protein interac-
tions [23,26,27].
Virion incorporation of A3G is required for its antiviral
activity and results in hypermutation of the viral minus-
strand cDNA during reverse transcription [3-6,21]. The
mechanism by which A3G is incorporated into viral parti-
cles has not been fully established. Some studies have
concluded that there is direct association between A3G
and HIV-1 Gag through the NC domain and a linker
sequence from A3G [28-30]. This was suggested by the
fact that deletions/mutation in Gag NC substantially
reduced the packaging of A3G into virus-like particles.
Others, including our group, showed that the presence of
viral or nonviral RNA is required for A3G-Gag co-IP [31-
35].
To determine the nature of A3G-A3G, A3G-RNA, and
A3G-Gag interactions, we developed a bimolecular fluo-
rescence complementation (BiFC) assay that allowed us
to analyze the interactions in living cells [36,37]. BiFC is
based on the association between nonfluorescent N- and
C-terminal fragments (NY and CY) of the monomeric yel-
low fluorescent protein that results in the reconstitution
of YFP and fluorescence. The NY and CY fragments have
very low affinity for each other; however, if NY and CY are
fused to other proteins that can multimerize, then the
association of the fusion proteins can result in BiFC. Thus,
interactions between proteins that may physically associ-
ate with each other can be studied in the intracellular
environment of a living cell. In these studies, we used the
BiFC assay to analyze A3G-Gag interactions and observed
that while wild-type A3G and Gag can reconstitute fluo-
rescence, RNA binding-defective mutants of Gag or A3G
failed to reconstitute fluorescence, indicating that both
A3G and Gag need to bind RNA for multimerization. We
also used the BiFC assay to analyze A3G-A3G interactions
and observed that wild-type A3G proteins can interact to
reconstitute fluorescence. Furthermore, wild-type A3G
and RNA binding-defective mutants of A3G form multim-
ers with a lower efficiency, suggesting that that RNA bind-
ing by one A3G may result in a low affinity interaction
with another A3G. These results indicate that A3G mole-
cules multimerize upon binding to RNA and that weak
interactions that occur upon RNA binding by one A3G
molecule may contribute to the stability of the multimers.
Results
Expression and characterization of A3G BiFC constructs
To analyze interactions between A3G and other macro-
molecules in living cells, we generated a series of A3G
BiFC constructs (Fig. 1A). A3G-NY and A3G-CY express
A3G that was fused to the NY or CY fragments of YFP at
the C-terminus, respectively; A3G and the YFP fragments
are separated by a 12 amino acid glycine-rich flexible
linker (PGISGGGGGILD). NY-A3G and CY-A3G express
A3G that is fused to the NY or CY fragments at the N-ter-
minus, respectively, and the A3G and YFP fragments are
separated by a slightly longer 19 amino acid glycine-rich
flexible linker (EGITGGGGILDGYLQNSR). We did not
determine whether the hinge regions are essential for
reconstitution of YFP fluorescence. To evaluate the expres-
sion of the A3G BiFC constructs, we implemented West-
ern blot analysis of transiently transfected 293T cells (Fig.
1B). The results showed that all BiFC fusion proteins were
expressed; the A3G-NY and NY-A3G proteins were
expressed at lower levels than the A3G-CY and CY-A3G
proteins. Because of the longer flexible linkers, the NY-
A3G and CY-A3G proteins are slightly larger than the
A3G-NY and A3G-CY proteins, respectively. To determine
whether fusion of NY and CY to A3G affected its cytidine
deaminase activity, we prepared lysates of cells transfected
with the BiFC constructs and measured the cytidine deam-
inase activity using a previously described scintillation
proximity assay (Fig. 1C). The results showed that cells
transfected with all four BiFC constructs had significantlyRetrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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higher levels of cytidine deaminase activity than in the
absence of A3G. The enzymatic activities detected were
above the linear range of the assay; as a result, differences
in expression levels between the fusion proteins were not
reflected in the enzymatic activities measured in the cell
lysates.
Next, we evaluated whether the A3G BiFC fusion proteins
inhibited HIV-1 replication (Fig. 1D). We cotransfected
293T cells with the A3G BiFC constructs in the presence of
pHDV-EGFP (an HIV-1 based vector that expresses EGFP),
pC-HelpΔVif (an HIV-1 helper construct that lacks several
cis-acting elements needed for viral replication and
A3G BiFC constructs and their biological activities Figure 1
A3G BiFC constructs and their biological activities. (A) Structures of A3G BiFC constructs A3G-NY, A3G-CY, NY-
A3G, and CY-A3G. The YFP N-terminal (NY) and C-terminal (CY) fragments were fused either to the C-terminal end of A3G 
(A3G-NY and A3G-CY) or the N-terminal end of A3G (NY-A3G and CY-A3G). The glycine-rich hinge regions (thin lines) for 
N-terminally tagged BiFC constructs is slightly longer than in the C-terminally tagged constructs. The catalytic domains 1 and 2 
(CD1 and CD2) are shown as gray boxes. (B) Western blotting analysis of cells co-transfected with HDV-EGFP along with 
wild-type A3G or A3G BiFC constructs. The A3G protein was detected using a polyclonal anti-A3G antibody. (C) Relative cyti-
dine deaminase activity in lysates of cells co-transfected with wild-type A3G or A3G BiFC constructs as well as pHDV-EGFP, 
pC-HelpΔVif and pHCMV-G. Total cellular protein (0.3 μg) from each cell lysate was used for determination of enzymatic activ-
ity, and the activity in cells transfected with wild-type A3G was set to 100%. Error bars represent the standard error of the 
mean (s.e.m.) of three independent experiments. (D) Effect of wild-type A3G and A3G BiFC constructs on infectivity of HDV-
EGFP. The infectivity of the virions produced in the absence and presence of HIV-1 Vif was determined by flow cytometry anal-
ysis of cells infected with the virions. Transfections were also performed in the absence of A3G and Vif, and the proportion of 
GFP+ cells after infection with HDV-EGFP (23.4% in the absence of Vif, and 28% in the presence of Vif) was set to 100%. Error 
bars represent the s.e.m. of three independent experiments.
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expresses all viral genes except Vif, Nef, and Env), and
pHCMV-G (a plasmid that expresses vesiculostomatitis
virus envelope glycoprotein G). The ability of the virions
produced to complete one cycle of replication was deter-
mined by infecting 293T cells and analyzing the infected
cells for GFP expression by flow cytometry. The propor-
tion of HDV-EGFP infected cells that were GFP-positive in
the absence of A3G (23.4% in the absence of Vif and 28%
in the presence of Vif) were set to 100%. In the absence of
Vif, cotransfection with wild-type A3G or A3G BiFC con-
structs resulted in severe reductions in GFP+  cells to
approximately 2 – 9% of the level observed when cells
were infected in the presence of Vif and wild-type A3G
(Fig. 1D). These results indicated that the A3G BiFC fusion
proteins were able to inhibit HIV-1 replication. In the
presence of Vif, the viral infectivity in the presence of wild-
type A3G, A3G-NY, and A3G-CY was 31 – 49% of that in
the absence of A3G. In the presence of Vif, the viral infec-
tivity in the presence of NY-A3G and CY-A3G was 16%,
which was 44% of the wild-type A3G control. This obser-
vation suggested that the N-terminally tagged A3G pro-
teins were more resistant to Vif than the wild-type or C-
terminally tagged A3G proteins. Nevertheless, all BiFC
fusion constructs were sensitive to Vif, since viral infectiv-
ity was higher in the presence of Vif compared to the infec-
tivity in the absence of Vif.
A3G BiFC fusion proteins multimerize and reconstitute 
fluorescence
To determine whether the A3G BiFC fusion proteins mul-
timerized in cells and reconstituted fluorescence, we
cotransfected HeLa cells with the A3G BiFC constructs in
different combinations (Fig. 2A). A mononmeric red fluo-
rescence protein-1 (mRFP1)-expressing plasmid was also
cotransfected and served as a control for the identification
of transfected cells (Fig. 2A, panels labeled RFP). All BiFC
assays to detect reconstitution of YFP fluorescence were
performed at 37°C. Cotransfection of A3G-NY and A3G-
CY (Fig. 2A-I) as well as NY-A3G and CY-A3G (Fig. 2A-II)
reconstituted fluorescence, indicating that the NY and CY
fragments that were fused at either the N- or C-terminus
of A3G interacted with each other to reconstitute fluores-
cence (Fig. 2A, panels labeled YFP). Interestingly, cotrans-
fection with A3G-NY and CY-A3G (Fig. 2A-III) as well as
NY-A3G and A3G-CY (Fig. 2A-IV) also reconstituted fluo-
rescence, indicating that the NY and CY fragments that
were fused to different termini of A3G also interacted to
reconstitute fluorescence. As expected, when each A3G
BiFC construct was transfected individually, fluorescence
was not reconstituted (Figs. 2A-V to 2A-VIII). In addition
to diffuse staining throughout the cytoplasm, we also
observed aggregations of all A3G fusion proteins (see Fig.
2A, panel I); these aggregates resembled previously
described association of A3G with P bodies, but further
studies are needed to verify the nature of the aggregations
Reconstitution of YFP fluorescence with A3G BiFC con- structs Figure 2
Reconstitution of YFP fluorescence with A3G BiFC 
constructs. (A) Reconstitution of fluorescence upon 
cotransfection with A3G BiFC constructs. HeLa cells were 
cotransfected with A3G BiFC constructs and mRFP expres-
sion plasmid to identify transfected cells. Fluorescence was 
reconstituted upon co-transfection with A3G-NY + A3G-CY 
(I), NY-A3G + CY-A3G (II), A3G-NY + CY-A3G (III), and 
NY-A3G + A3G-CY (IV). Transfection with A3G-NY (V), 
A3G-CY (VI), NY-A3G (VII), or CY-A3G (VIII) did not pro-
duce YFP fluorescence. (B) Quantfication of BiFC using flow 
cytometry analysis. 293T cells were co-transfected with A3G 
BiFC constructs and mRFP expression plasmid as an internal 
control for transfection, and the percentage of YFP+ cells in 
mRFP+ cells was determined. The percentage of YFP+ cells in 
mRFP+ cells after co-transfection with A3G-NY and A3G-CY 
(15.3%) was set to 100%. The error bars represent the s.e.m. 
of two independent experiments.Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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[24,25,38,39]. The appearance of the A3G aggregations in
the figures depended on the z-series slice that was used to
create the figure, but most cells that showed YFP fluores-
cence also showed the A3G aggregations.
To determine BiFC efficiency, we performed fluorescence
activating cell scanning (FACS) analysis of cells trans-
fected with various BiFC constructs and mRFP expressing
plasmid and determined the proportions of YFP+ cells in
transfected mRFP+ cells (Fig. 2B). Co-transfection with
A3G-NY and A3G-CY reconstituted YFP fluorescence in
15% of the mRFP+ cells (set to 100%). Transfection with
NY-A3G and CY-A3G resulted in YFP reconstitution with
a similar efficiency (89%). Reconstitution of YFP fluores-
cence between A3G-NY and CY-A3G was less efficient
(37%), whereas YFP fluorescence was reconstituted more
efficiently between A3G-CY and NY-A3G (193%). The dif-
ferences in the efficiency of YFP fluorescence reconstitu-
tion may be due to the orientations of the NY and CY
fusion proteins in the complexes. When the A3G-NY,
A3G-CY, NY-A3G, and CY-A3G constructs were trans-
fected individually, less than 0.1% of the cells expressed
YFP fluorescence, indicating that interactions between the
NY and CY fragments mediated by A3G were necessary to
achieve efficient YFP reconstitution.
Characterization of A3G BiFC constructs containing CD1 
and CD2 mutations
The CD1 of A3G has been shown to be important for RNA
binding and virion incorporation [18], whereas CD2 has
been shown to possess cytidine deaminase activity [17].
To evaluate the role of CD1 and CD2 in A3G multimeri-
zation, we generated a series of BiFC constructs containing
mutations in either the CD1 or the CD2. The CD1 resi-
dues H65 and C97 were substituted with arginine or ser-
ine, respectively, to generate H65R-NY, H65R-CY, C97S-
NY, and C97S-CY. Similarly, the CD2 residues H257 and
C288 were substituted with arginine and serine, respec-
tively, to generate H257R-NY, H257R-CY, C288S-NY, and
C288S-CY.
To determine the effects of the CD1 and CD2 mutations
on expression of the A3G BiFC constructs, we transiently
transfected 293T cells with the constructs and analyzed
the expression of the A3G BiFC fusion proteins by western
blotting (Fig. 3A). Preliminary experiments indicated that
the A3G BiFC constructs containing the CD1 mutations
were expressed at approximately fourfold lower steady-
state levels than the wild-type A3G BiFC constructs (data
not shown). We therefore transfected fourfold higher
amounts of the A3G BiFC constructs containing the CD1
mutations and analyzed the steady-state levels of A3G
fusion protein expression. The results showed that after
adjusting the amount of plasmid DNA used in the trans-
fection, the levels of the NY fusion proteins were compa-
A3G BiFC constructs containing mutations in CD1 or CD2  and their biological activities Figure 3
A3G BiFC constructs containing mutations in CD1 
or CD2 and their biological activities. (A) Western 
blotting analysis of lysates of 293T cells and viral lysates pro-
duced from cells co-transfected with pHDV-EGFP, pC-Help-
ΔVif and pHCMV-G and wild-type A3G or A3G BiFC 
constructs containing mutations in the CD1 (H65R-NY, 
H65R-CY, C97S-NY, and C97S-CY) or CD2 (H257R-NY, 
H257R-CY, C288S-NY, and C288S-CY). The cell lysates 
were also analyzed using anti-tubulin antibody to insure 
equivalent loading of cell lysate proteins (panel labeled α-
tubulin). (B) Effects of CD1 or CD2 mutations on A3G's abil-
ity to inhibit HIV-1 replication. 293T cells were co-trans-
fected with wild-type A3G or A3G BiFC constructs along 
with pHDV-EGFP, pC-HelpΔVif, and pHCMV-G, and the 
infectivity of the virions produced was determined by flow 
cytometry analysis of the infected cells for EGFP expression. 
The proportion of GFP+ cells in the absence of A3G co-
transfection was set to 100%. Error bars represent the s.e.m. 
of three independent experiments. (C) Vif sensitivity of CD1 
domain mutants. A3G-CY and CD1 domain mutants H65R-
CY, F70A-CY, and Y91A-CY were transfected into 293T 
cells with and without Vif expression plasmid. A3G fusion 
proteins were detected by using anti-A3G antibody and HIV-
1 Vif was detected using anti-Vif polyclonal antiserum. Anti-
tubulin antibody was used to detect tubulin, which served as 
a loading control.Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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rable in the cell lysates (Fig. 3A, upper panel). Similarly,
the CY fusion proteins were expressed at similar levels in
the cell lysates (Fig. 3A, lower panel).
Next, we determined the effects of the CD1 and CD2
mutations on virion incorporation of the A3G BiFC fusion
proteins (Fig. 3A). The virions produced from the trans-
fected 293T cells were isolated and equivalent amounts of
virions, as determined by p24 capsid (CA) amounts, were
analyzed by western blotting. As expected, the results
showed that the wild-type A3G and the CD2 mutant BiFC
fusion proteins were incorporated into virions, whereas
the CD1 mutant BiFC fusion proteins were severely defec-
tive in virion incorporation (Fig. 3A, upper and lower pan-
els labeled viral lysate).
Next, we determined whether the CD1 and CD2 muta-
tions influenced the ability of the A3G BiFC constructs to
inhibit HIV-1 replication (Fig. 3B). In contrast to wild-
type A3G, all of the CD1 and CD2 mutants were severely
defective in their ability to inhibit HIV-1 replication.
These results are consistent with our observations that the
CD1 mutants are defective in virion incorporation (Fig.
3A) and that the CD2 mutants exhibit little or no cytidine
deaminase activity (data not shown).
The F70 and Y91 amino acids in the CD1 domain has
been previously implicated to be involved in RNA binding
[15,18]. We sought to determine whether the RNA-bind-
ing defective mutants H65R-CY, F70A-CY, and Y91A-CY
are sensitive to Vif binding and proteasomal degradation
(Fig. 3C). We cotransfected A3G-CY, H65R-CY, F70A-CY,
and Y91A-CY in the presence or absence of pcDNA-hVif, a
codon-optimized Vif expression vector [40], and per-
formed western blot analysis. The A3G fusion proteins
could be readily detected in the cells in the absence of Vif,
but could not be detected in the presence of Vif. The
results confirmed that these fusion proteins are sensitive
to Vif-mediated proteasomal degradation.
It has been previously shown that co-IP of A3G proteins
tagged with different epitopes is sensitive to RNase A treat-
ment [22,26]. To directly determine the effect of CD1
mutations on RNA binding, we performed co-IP assays
from lysates of cells transfected with wild-type A3G that
was tagged at the N-terminus with the FLAG epitope (F-
A3G) and either H65R-CY or F70A-CY (Fig. 4A). In addi-
tion, the co-IP assays were performed before or after treat-
ment of cell lysates with RNase A to degrade cellular RNA.
The co-IPs were performed using an anti-FLAG antibody,
and the A3G proteins were detected by western blot using
an anti-A3G antibody. As expected, A3G-CY was effi-
ciently co-immunoprecipitated in the absence of RNase A
treatment; in contrast, upon RNase A treatment, very little
A3G-CY was co-immunoprecipitated, indicating that its
interaction with F-A3G was mediated through RNA bind-
ing. The faint A3G-CY band detected after RNase A treat-
ment is most likely due to incomplete degradation of
RNA, since several other co-IP experiments with wild-type
A3G proteins did not produce detectable bands after
excess RNase A treatment (see Figs. 4B, C, D, and 6B). In
contrast to A3G-CY, little or no H65R-CY and F70A-CY
were co-immunoprecipitated with F-A3G in the absence
of RNase A treatment. The observation indicated that the
RNA-dependent interaction between A3G-CY and F-A3G
was reduced or eliminated when the H65R or F70A muta-
tion was introduced in the A3G-CY. One likely explana-
tion for the loss of interaction with F-A3G is that the
H65R-CY and F70A-CY are defective in RNA binding,
which results in a loss of the RNA-dependent interaction.
To determine the possible effects of the C-terminal CY tag
on A3G-A3G interactions, we performed co-IP assays with
F-A3G and untagged wild-type A3G or untagged H65R
mutant A3G (Fig. 4B). The results were identical to those
obtained with the A3G-CY and H65R-CY proteins; the
wild-type untagged A3G was co-immunoprecipitated with
F-A3G in the presence of RNA, but not in the absence of
RNA. The untagged H65R mutant A3G was not co-immu-
noprecipitated with F-A3G in the presence or absence of
RNA. To explore the effects of N-terminal tags on A3G-
A3G interactions, we co-immunoprecipitated NY-A3G
and CY-A3G with F-A3G (Fig. 4C). The result indicated
that both of the N-terminally tagged proteins were co-
immunoprecipitated with A3G in the presence of RNA but
not in the absence of RNA. Thus, similar results obtained
with C-terminally tagged, N-terminally tagged, and
untagged A3G indicated that A3G-A3G interactions could
be detected in the presence of RNA, but the interaction
could not be detected if the cell lysates were treated with
RNase A to degrade cellular RNA.
We also determined the ability of CD2 mutants H257R-
CY and C288S-CY to bind to RNA by performing co-IP
assays on lysates of cells transfected with F-A3G and either
A3G-CY, H257R-CY, or C288S-CY (Fig. 4D). The results
showed that in the absence of RNase A treatment, both
H257R-CY and C288S-CY could be co-immunoprecipi-
tated with F-A3G; however, after RNase A treatment, the
H257R-CY and C288S-CY could not be co-immunopre-
cipitated with F-A3G. The result indicated that these CD2
mutants retained their ability to interact with A3G in the
presence of RNA.
Effects of CD1 and CD2 mutations on A3G 
multimerization
We sought to determine whether the CD1 and CD2 muta-
tions in the A3G BiFC constructs influenced their ability
to form multimers in living cells and reconstitute fluores-
cence. To determine the effects of the CD2 mutations, weRetrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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cotransfected HeLa cells with H257R-NY and H257R-CY
mutants (Fig. 5A-I) or with C288S-NY and C288S-CY
mutants (Fig. 5A-II). In both cases, the CD2 mutants inter-
acted with each other and reconstituted fluorescence. In
addition, we also cotransfected H257R-NY and C288S-CY
(Fig. 5A-III) or C288S-NY and H257R-CY (Fig. 5A-IV) and
observed that the two different CD2 mutants interacted to
reconstitute fluorescence. These results indicated that
CD2 mutations do not affect the ability of the A3G BiFC
fusion proteins to form multimers. Transfection of the
individual CD2 mutants tagged with the NY or CY frag-
ment failed to produce fluorescence, indicating that BiFC
was required to reconstitute fluorescence (Fig. 5A, panels
V – VIII).
RNA binding activities of CD1 and CD2 domain mutants of A3G Figure 4
RNA binding activities of CD1 and CD2 domain mutants of A3G. (A) Effect of CD1 mutations on the ability of A3G 
to bind cellular RNA. 293T cells were co-transfected with pF-A3G and empty vector, or pF-A3G and A3G-CY, or pF-A3G and 
fourfold higher amounts of H65R-CY or F70A-CY DNA compared to pF-A3G. An anti-FLAG antibody was used to co-immu-
noprecipitate F-A3G and associated proteins in the presence or absence of RNase A treatment. The F-A3G, A3G-CY, H65R-
CY, and F70A-CY proteins were detected by Western blot using an anti-A3G antibody. (B) A3G-A3G interactions between F-
A3G and untagged A3G proteins. 293T cells were co-transfected with F-A3G and empty vector, F-A3G and fourfold higher 
amounts of untagged A3G DNA or F-A3G and fourfold higher amounts of untagged H65R mutant of A3G DNA. Co-IP assays 
were performed as described in Fig. 4A. (C) Effect of N-terminal NY and CY tags on A3G-A3G interactions. 293T cells were 
co-transfected with F-A3G and NY-A3G or CY-A3G. Co-IP assays were performed as described in Fig. 4A. (D) Effect of CD2 
mutations on ability of A3G to bind to RNA. 293T cells were co-transfected with pF-A3G and empty vector, or pF-A3G and 
A3G-CY, or pF-A3G and fourfold higher amounts of H257R-CY, and C288S-CY DNA compared to pF-A3G. Co-IP assays 
were performed as described in Fig. 4A.Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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BiFC assays with CD1 and CD2 mutants of A3G Figure 5
BiFC assays with CD1 and CD2 mutants of A3G. (A) BiFC assays with CD2 mutants of A3G. All co-transfections 
included mRFP expressing plasmid, and RFP expression was used to identify transfected cells (panels labeled RFP). (B) BiFC and 
immunofluorescence assays with CD1 mutants of A3G. Expression of the CD1 mutants was verified by detection of the H65R-
NY, H65R-CY, C97S-NY, and C97S-CY proteins in transfected cells by immunofluorescence. An anti-A3G polyclonal antibody 
produced in rabbit was used as a primary antibody and Alexa Fluor 568-conjugated goat antibody to rabbit IgG (H+L) (Molec-
ular Probes) was used as secondary fluorescent antibody. (C) Comparison of BiFC and protein expression between WT A3G 
and H65R mutant A3G. Western blotting analysis of lysates of cells co-transfected with A3G-NY and -CY (I, 0.25 μg DNA 
each) or H65R-NY and -CY (II, 1 μg DNA each). The A3G proteins were identified by using a polyclonal anti-A3G antibody, 
and the same lysates were analyzed by using an anti-tubulin antibody to ensure that equivalent amounts were loaded onto gels. 
(D) Western blotting analysis of lysates of 293T cells and viral lysates produced from cells transfected with CD1 mutants 
F70A-NY, F70A-CY, Y91A-NY, and Y91A-CY. The cell lysates were also analyzed using anti-tubulin antibody to insure equiva-
lent loading of cell lysate proteins (panel labeled α-tubulin). (E) BiFC assays with CD1 mutants F70A and Y91A.Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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We then determined the effects of the CD1 mutations on
the ability of the A3G BiFC fusion proteins to interact and
reconstitute fluorescence. We cotransfected HeLa cells
with H65R-NY and H65R-CY (Fig. 5B-I), C97S-NY and
C97S-CY (Fig. 5B-II), or H65R-NY + C97S-CY (Fig. 5B-
III). In contrast to the CD2 mutants, the CD1 domain
mutants failed to reconstitute fluorescence (Fig. 5B, pan-
els labeled YFP). To verify that the CD1 mutants were
expressed in the cotransfected HeLa cells, we performed
immunofluorescence studies using an anti-A3G polyclo-
nal antiserum to detect A3G expression (Fig. 5B). The
results showed that expression of H65R-NY, H65R-CY,
C97S-NY, C97S-CY, and wild-type A3G is readily detecta-
ble, and indicated that the absence of YFP fluorescence in
cells transfected with these constructs is not due to a lack
of expression.
To further verify that lower levels of expression of the CD1
mutants are not responsible for the absence of BiFC-gen-
erated YFP fluorescence, we transfected either 0.25 μg
each of the control A3G-NY and A3G-CY constructs, or
1.0 μg each of the H65R-NY and H65R-CY constructs (Fig.
5C-I and 5C-II). Western blotting analysis showed that the
amounts of A3G-NY and H65R-NY proteins were similar
to each other in the transfected cells. Additionally, the
amounts of A3G-CY and H65R-CY proteins were similar
to each other. Co-transfection of HeLa cells with 0.25 μg
each of the A3G-NY and A3G-CY constructs resulted in
reconstitution of fluorescence (Fig. 5C-III). However, co-
transfection of HeLa cells with 1.0 μg each of the H65R-
NY and H65R-CY constructs did not reconstitute fluores-
cence (Fig. 5C-IV). These results indicated that the absence
of fluorescence in cells cotransfected with H65R-NY and
H65R-CY is not due to the lower expression levels of the
CD1 domain mutants.
The CD1 mutations H65R and C97S alter the amino acids
involved in the zinc-binding H-X-E-x23–28-Cx2–4-C motif;
consequently, these mutations could potentially affect the
overall structure of the N-terminal CD1 and prevent
reconstitution of fluorescence through other effects not
involving RNA binding. To address this concern, we gen-
erated F70A-NY, F70A-CY, Y91A-NY, and Y91A-CY con-
structs that had mutations of the aromatic residues F70
and Y91 that were previously implicated as being critical
for RNA binding [18,41]. Western blotting analysis of cell
lystates indicated that the NY and CY fusion proteins con-
taining these mutations were expressed (Fig. 5D). How-
ever, these mutants failed to reconstitute fluorescence
(Fig. 5E) and further supported the conclusion that A3G
RNA binding is essential for multimerization. The F70A-
NY and Y91A-NY reconstituted weak fluorescence with
wild-type A3G-CY, indicating that the lower expression
level of these mutants was not responsible for the lack of
fluorescence (shown in Fig. 10).
Fusion of RNA-binding peptide to H65R mutant of A3G 
restores BiFC
To determine whether RNA binding of A3G is sufficient to
restore BiFC, we generated expression constructs in which
P22, a non-specific RNA binding peptide (GNAK-
TRRHERRRKLAIERDTIGYS), was inserted between the
initiation AUG codon and the second codon of the CD1
mutants H65R-NY and H65R-CY (Fig. 6A). The P22 pep-
tide was derived from the P22 bacteriophage, which spe-
cifically associates with a stemloop with high affinity in
vitro [42,43]. However, the P22 peptide binds to RNA in
a non-specific manner (V. Boyko and W.-S. Hu, unpub-
lished observations).
We determined whether the P22 peptide restored the RNA
binding ability of the H65R-CY mutant by performing co-
IP assays on lysates of cells cotransfected with F-A3G and
either A3G-CY or P22-H65R-CY (Fig. 6B). The results
showed that in the absence of RNase A treatment, both
A3G-CY and P22-H65R-CY could be co-immunoprecipi-
tated with F-A3G; however, after RNase A treatment, nei-
ther A3G-CY nor P22-H65R-CY protein were co-
immunoprecipitated with F-A3G. As shown in Fig. 4A, the
H65R-CY protein could not be co-immunoprecipitated
with F-A3G. The result indicated that addition of the P22
peptide to the H65R mutant restored its RNA-dependent
interaction with F-A3G.
Next, we determined whether the presence of the P22 pep-
tide restored the ability of the H65R mutant to multimer-
ize and reconstitute fluorescence (Fig. 6C). As observed
earlier, co-transfection of HeLa cells with A3G-NY and
A3G-CY reconstituted fluorescence (Fig. 6C-I), while co-
transfection with H65R-NY and H65R-CY failed to recon-
stitute fluorescence (Fig. 6C-II). In contrast to the results
obtained with H65R-NY and H65R-CY, co-transfection of
HeLa cells with P22-H65R-NY and P22-H65R-CY recon-
stituted fluorescence (Fig. 6C-III). When we co-transfected
A3G-NY and P22-H65R-CY, fluorescence was also
restored (Fig. 6C-IV), indicating that protein-protein
interactions between the P22 peptides in the fusion pro-
teins were not responsible for reconstitution of fluores-
cence between P22-H65R-NY and P22-H65R-CY.
We sought to determine whether the P22 peptide restored
virion incorporation of the H65R CD1 mutant. The P22-
H65R-NY and P22-H65R-CY constructs were expressed at
low levels (data not shown); we therefore generated P22-
A3G and P22-H65R, constructs that expressed the P22
peptide at their N-terminus but were not fused to the NY
or CY fragments of YFP (Fig. 7A). We then determined the
cellular expression and virion incorporation of these con-
structs (Fig. 7B). The results indicated that the P22-A3G
construct was expressed at a level that was similar to
untagged A3G, while the P22-H65R and H65R proteinsRetrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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were expressed at lower levels. Analysis of the viral lysates
indicated that the P22-A3G was incorporated more effi-
ciently into virions than wild-type A3G. In contrast to the
H65R protein, the P22-H65R protein was efficiently
incorporated into virions, indicating that the presence of
the P22 peptide was sufficient to overcome the virion
incorporation defect induced by the H65R mutation.
We sought to determine whether the P22-A3G and P22-
H65R proteins were enzymatically active (Fig. 7C). The
cytidine deaminase activities in viral lysates containing
these proteins were similar to the A3G control, indicating
that the presence of the P22 peptide did not interfere with
the in vitro cytidine deaminase activity. The P22-H65R
protein exhibited more cytidine deaminase activity in the
viral lysates than the H65R mutant protein, consistent
with the Western blotting analysis indicating that the P22-
H65R mutant A3G was packaged into virions more effi-
ciently than the H65R mutant A3G.
Finally, we examined whether the presence of the P22
peptide increased the ability of the CD1 domain mutants
to inhibit HIV-1 replication (Fig. 7D). The P22-A3G pro-
tein was a potent inhibitor of HIV-1 replication in the
absence of Vif, indicating that the presence of the P22 pep-
tide did not interfere with the antiviral activity of the A3G
protein. On the other hand, the P22-H65R protein did not
inhibit HIV-1 replication, despite the fact that it was effi-
ciently packaged into the virions. The results suggested
that while the P22 peptide restored virion incorporation,
it was not sufficient to overcome the defect in antiviral
activity induced by the H65R mutation.
A3G and HIV-1 Gag multimerize to reconstitute 
fluorescence
Several studies have reported that A3G and HIV-1 Gag can
be co-immunoprecipitated from cells [27-32,44]. Some
studies have shown that these interactions are sensitive to
treatment with RNase A, suggesting that the interactions
are mediated through an RNA bridge [31,32,34], while
others have reported that the co-IP is insensitive to RNase
A treatment, and that A3G and the NC domain of HIV-1
Gag interact directly [28,30]. We probed the nature of
A3G and HIV-1 Gag interactions in living cells by using
BiFC. We used HIV-1 Gag BiFC constructs Gag-NY and
Gag-CY in which either the NY or CY fragment of YFP was
fused to HIV-1 Gag at its C-terminus; we also generated
Gag-NC* -NY and Gag-NC*-CY constructs in which the
NC domain of HIV-1 Gag contained C28H and H44C
mutations in the NC zinc finger domains; mutations in
the NC zinc finger domains were previously shown to sig-
nificantly reduce RNA binding (Fig. 8A) [31,45-48]. West-
ern blotting analysis of 293T cells transfected with the
HIV-1 Gag expression constructs showed that all four of
the HIV-1 Gag fusion proteins were expressed (Fig. 8B).
Effect of non-specific RNA-binding peptide on BiFC with  CD1 mutant H65R Figure 6
Effect of non-specific RNA-binding peptide on BiFC 
with CD1 mutant H65R. (A) Structure of P22-H65R BiFC 
constructs. P22 is a 20-amino-acid basic peptide derived from 
bacteriophage P22 that was fused to the N-terminus of 
H65R-NY and H65R-CY with a flexible hinge region between 
P22 and A3G. (B) Effect of P22 peptide on ability of H65R 
mutant to bind to RNA. 293T cells were co-transfected with 
pF-A3G and empty vector, or pF-A3G and A3G-CY, or pF-
A3G and fourfold higher amount of P22-H65R-CY compared 
to pF-A3G. Co-IP assays were performed as described for 
Fig. 4A. (C) BiFC assays to evaluate interactions between 
wild-type and mutant A3Gs.Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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We determined the ability of the A3G fusion proteins to
interact with the HIV-1 Gag fusion proteins to reconstitute
fluorescence (Fig. 8C). The results showed that both A3G-
NY and NY-A3G interacted with Gag-CY to reconstitute
fluorescence (Fig. 8C-I and 8C-II). Similarly, both A3G-
CY and CY-A3G interacted with Gag-NY to reconstitute
fluorescence (Fig. 8C-III and 8C-IV).
We then sought to determine whether the CD1 and CD2
mutations in A3G influenced their ability to interact with
HIV-1 Gag BiFC constructs to reconstitute YFP and fluo-
rescence (Fig. 8D). The CD1 mutants H65R-CY and C97S-
CY did not interact with Gag-NY and failed to reconstitute
fluorescence (Fig. 8D-I and 8D-II), while the CD2
mutants H257R-CY and C288S-CY interacted with Gag-
NY and reconstituted fluorescence (Fig. 8D-III and 8D-
IV). We also asked whether the addition of the P22 pep-
tide to the CD1 mutant H65R restored its ability to inter-
act with HIV-1 Gag to reconstitute fluorescence. The
results showed that the P22-H65R-NY + Gag-CY (Fig. 8D-
V) and P22-H65R-CY + Gag-NY (Fig. 8D-VI) interacted to
reconstitute fluorescence. These results suggested that
A3G's ability to bind to RNA was essential and sufficient
for its ability to multimerize with Gag.
Effect of non-specific RNA-binding peptide on encapsidation and antiviral activity of CD1 mutant H65R Figure 7
Effect of non-specific RNA-binding peptide on encapsidation and antiviral activity of CD1 mutant H65R. (A) 
Strucures of constructs P22-H65R, H65R, P22-A3G, and wild-type A3G. (B) Western blotting analysis of lysates of 293T cells 
co-transfected with the A3G constructs as well as pHDV-EGFP, C-HelpΔVif and pHCMV-G (panel labeled Cell lysate). The cell 
lysates were also analyzed using anti-tubulin antibody to insure equivalent loading of cell lysate proteins (panel labeled α-tubu-
lin). Incorporation of A3G BiFC constructs into VLPs (panel labeled Viral lysate) was determined by analyzing viral lysates con-
taining 100 ng of p24 CA. (C) Relative cytidine deaminase activity in viral lysates of virions produced in the presence of wild 
type A3G, P22-A3G, P22-H65R, H65R, or in the absence of A3G. The cytidine deaminase activity of A3G-CY was set to 100%. 
(D) Relative HDV-EGFP infectivity in the presence of P22-A3G, P22-H65R and H65R constructs. Infectivity of the virions pro-
duced was determined by flow cytometry analysis of cells infected with the virions. The proportion of GFP+ cells after infection 
with HDV-EGFP in the absence of A3G was set to 100%. Error bars represent the s.e.m. of three independent experiments.Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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We also determined whether CD1 domain mutants that
were defective in RNA binding, H65R-NY, F70A-NY and
Y91A-NY could interact with Gag-CY to reconstitute YFP
fluorescence (Fig. 9A). The results showed that H65R-NY
(Fig. 9A-II), F70A-NY (Fig. 9A-III), or Y91A-NY (Fig. 9A-
IV) did not reconstitute fluorescence with Gag-CY.
Finally, we asked whether the ability of HIV-1 Gag to bind
RNA influences its ability to multimerize with A3G. Co-
transfection of Gag-NC*-NY + A3G-CY, A3G-NY + Gag-
NC*-CY, NY-A3G + Gag-NC*-CY, and Gag-NC*-NY + CY-
A3G (Fig. 9B-I to 9B-IV) failed to reconstitute fluores-
cence. These results indicated that the mutations in NC,
which were previously shown to impair Gag's ability to
bind to RNA [31], interfered with Gag's ability to mul-
timerize with A3G.
We performed FACS analysis to quantify the efficiency of
YFP fluorescence reconstitution between Gag and A3G
proteins (Fig. 9C). YFP fluorescence reconstitution with
Characterization of HIV-1 Gag BiFC constructs and interactions with A3G Figure 8
Characterization of HIV-1 Gag BiFC constructs and interactions with A3G. (A) Structure of HIV-1 Gag BiFC con-
structs. NC*, RNA-binding defective mutant of HIV-1 Gag. (B) Western blot analysis of HIV-1 Gag expression from BiFC con-
structs (anti-HIV-Gag polyclonal antibody) and α-tubulin in transfected 293T cells. (C) BiFC assays to evaluate interactions 
between HIV-1 Gag and wild-type A3G. (D) BiFC assays to evaluate interactions between HIV-1 Gag and CD1 or CD2 domain 
mutants of A3G.Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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Gag-NY and Gag-CY was less efficient (~3.3%) than YFP
reconstitution between A3G-NY and A3G-CY proteins
(15.3%). The reason for the lower efficiency of YFP recon-
stitution is not known, but it may be due to virus budding
and release, which result in lower steady-state levels of the
Gag proteins in cells. Despite the low efficiency, the per-
centage of YFP+ cells among mRFP+ cells was significantly
higher for Gag and A3G fusion proteins that were both
competent to bind to RNA compared to the experiments
in which one of the fusion proteins was defective in RNA
binding (<0.1%).
RNA-binding competent A3G proteins can multimerize 
with RNA-binding defective CD1 mutants
We sought to determine whether CD1 mutant proteins
can multimerize with CD2 mutants to reconstitute fluo-
rescence. We co-transfected H65R-NY along with H257R-
CY or C288S-CY (Fig. 10-I and 10-II), and C97S-NY with
H257R-CY or C288S-CY (Fig. 10-III and 10-IV). Although
the H65R-NY and the H65R-CY proteins failed to recon-
stitute fluorescence (Fig. 5B-I), they reconstituted weak
fluorescence with the RNA-binding competent CD2
mutants. Similarly, the RNA-binding defective mutants
F70A-NY, Y91A-NY, and H65R-NY reconstituted weak
fluorescence with wild-type A3G-CY (Fig. 10-V, -VI, and
10-VII). As expected, the control wild-type A3G-NY and
A3G-CY proteins reconstituted strong fluorescence (Fig.
10-VIII). These results indicated that when one of the A3G
molecules binds RNA, it can interact with RNA binding
defective mutants of A3G to reconstitute weak fluores-
cence.
The level of fluorescence reconstitution was significantly
weaker when one of the A3G fusion proteins was defective
in RNA binding; because of the lower level of fluorescence
reconstituted, the number of YFP+ cells that displayed flu-
orescence above the threshold of detection was also signif-
icantly lower. We quantified the efficiency of BiFC by
FACS analysis to determine the percentage of mRFP+ cells
that were YFP+ (Fig. 10B). The results showed that when
A3G-NY and A3G-CY were co-expressed, YFP fluorescence
was reconstituted in 95% of the mRFP-positive cells (set
to 100%). When both fusion proteins were unable to bind
to RNA (H65R-NY + H65R-CY, F70A-NY + F70A-CY, and
Y91A-NY + Y91A-CY), less than 0.1% of the mRFP+ cells
were YFP+. As noted above, when one of the A3G fusion
proteins was RNA-binding competent and the other
fusion protein was RNA-binding defective (H65R-NY +
A3G-CY, F70A-NY + A3G-CY, and Y91A-NY + A3G-CY),
fluorescence was reconstituted in 35 – 40% of the mRFP+
cells. To quantify the efficiency of BiFC reconstitution, we
also compared the mean fluorescence intensity of the
YFP+ cells (Fig. 10C). The results showed that compared to
the A3G-NY and A3G-CY positive control, the fluores-
cence intensity of YFP+ cells was 10–15% when the cells
BiFC assays to evaluate interactions between HIV-1 Gag,  A3G, and RNA-binding defective mutants of Gag and A3G Figure 9
BiFC assays to evaluate interactions between HIV-1 
Gag, A3G, and RNA-binding defective mutants of 
Gag and A3G. (E) BiFC assays to evaluate interactions 
between HIV-1 Gag and RNA-binding defective A3G mutants 
H65R, F70A, and Y91A. (F) BiFC assays to evaluate interac-
tions between HIV-1 Gag NC mutants and A3G. (G) Quanti-
fication of YFP fluorescence reconstitution with HIV-1 Gag 
and A3G BiFC constructs using flow cytometry analysis. The 
percentage of YFP+ cells in mRFP+ cells after co-transfection 
with Gag-NY and Gag-CY (3.5%) was set to 100%. The error 
bars represent the s.e.m. of two independent experiments.Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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expressed A3G-CY and RNA-binding defective mutants
H65R-NY, F70A-NY or Y91A-NY. The quantification of
the YFP+ cells as well as their mean fluorescence intensities
confirmed that the fluorescence reconstituted between
wild-type A3G and RNA-binding defective mutants is
weaker than that observed between two wild-type A3G
molecules but stronger than that observed between two
RNA-binding defective mutants.
Discussion
In these studies, we have established a robust BiFC assay
to analyze intracellular interactions between A3G and
other macromolecules. We previously used the BiFC assay
to demonstrate the co-assembly of HIV-1 and HIV-2 Gag
proteins, and others have observed interactions between
EIAV and HIV-1 Gag proteins and actin [49,50]. Our stud-
ies showed that fusion of NY or CY fragments to either the
N- or C-terminus of A3G did not significantly influence
A3G's ability to inhibit HIV-1 replication. Co-expression
of the NY and CY fusion proteins resulted in reconstitu-
tion of BiFC, indicating that A3G formed dimers or mul-
timers in cells.
Interestingly, fluorescence was reconstituted when the NY
and CY fragments were fused to the same terminal end or
at opposite terminal ends. The distance between the N-
and C-termini of the full-length A3G is not known; there-
fore, it is unclear whether the long flexible linkers will
allow reconstitution of YFP fluorescence regardless of the
orientation and physical proximity of the N- and C-ter-
mini. It was recently observed that purified A3G forms
tail-to-tail dimers, in which the C-terminal ends are close
to each other [26,27]. Assuming that physical proximity is
needed to reconstitute YFP fluorescence, our studies sug-
gest that in the presence of RNA, head-to-head and head-
to-tail dimers may also form.
A3G multimerization is dependent on RNA binding
Our results showed that A3G multimerization was
dependent on an intact CD1 while mutations in the CD2
did not influence multimerization. Co-IP assays also con-
firmed and extended previous observations indicating
that the CD1 mutants are defective in RNA binding [25].
The observation that the CD1 mutants failed to reconsti-
tute fluorescence in cells strongly suggested that interac-
tions between A3G molecules in cells are dependent on
RNA binding. These observations are consistent with pre-
vious biochemical studies, which showed that co-IP of
A3G molecules is eliminated upon treatment of cell
lysates with RNase A [22,25], and recent observations of
RNA-dependent oligomerization of A3G in intracellular
fluorescence resonance energy transfer [35] and co-IP
assays [51]. However, another recent study observed A3G-
A3G interactions in the presence of excess RNase A with
BiFC assays to evaluate interactions between RNA-binding  competent A3G proteins and RNA-binding defective A3G  proteins Figure 10
BiFC assays to evaluate interactions between RNA-
binding competent A3G proteins and RNA-binding 
defective A3G proteins. (A) BiFC assays to evaluate inter-
actions between mutant A3Gs. (B) Quantification of BiFC 
efficiency was determined by flow cytometry analysis as 
described in Fig. 2B. The percentage of YFP+ cells among the 
mRFP+ cells after cotransfection with A3G-NY and A3G-CY 
(15.3%) was set to 100%. The error bars represent the s.e.m. 
of two independent experiments. (C) Quantification of BiFC 
fluorescence mean intensity using flow cytometry analysis. 
The mean intensities of YFP+ cells were determined using 
CELLQUEST software. The error bars represent the s.e.m. 
of two independent experiments.
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wild-type A3G as well as C-terminal fragments of A3G
containing the CD2 domain [27]. To exclude the possibil-
ity that C-terminal tags in our constructs interfered with
RNA-independent A3G-A3G interactions, we carried out
co-IP studies with untagged A3G and N-terminally tagged
A3G constructs. We did not observe significant RNA-inde-
pendent co-immunoprecipitations between these con-
structs, indicating that the C-terminal tags were not
responsible for the lack of co-immunoprecipitation. The
reason for the differences between our results and those of
Bennett and coworkers is not clear, but may be due to dif-
ferences in assay conditions.
We observed that three different RNA-binding defective
mutants reconstituted weak fluorescence with wild-type
A3G and with CD2 domain mutants of A3G. These obser-
vations suggest that when one A3G molecule binds RNA,
it undergoes a conformational change that can permit a
weak protein-protein interaction with another A3G mole-
cule that may or may not be associated with RNA. The
nature of this weak interaction is not known, but one pos-
sibility is that the weak interactions could involve previ-
ously described in vitro protein-protein interactions
between A3G molecules and in vivo interactions between
C-terminal halves of A3G [23,26,27]. These weak interac-
tions were not detected in our co-IP assays (Fig. 4), sug-
gesting that they may be transient and are not stable
enough to be retained during the co-IP assays. Further
studies are needed to determine the nature and functional
relevance of these weak interactions. Taken together, our
results are consistent with a model in which A3G mole-
cules are monomeric in the absence of RNA and that upon
binding to RNA, conformational changes allow them to
interact with each other through weak protein-protein
interactions.
We considered the hypothesis that the RNA binding defec-
tive mutants we tested resulted in the expression of mis-
folded proteins, resulting in the loss of a direct protein-
protein interaction. We believe this explanation is
unlikely for several reasons. First, it is unlikely that all
three CD1 domain mutations (H65R, F70A, and Y91A)
caused conformational changes that resulted in the loss of
a direct protein-protein interaction. Second, all three
mutants were sensitive to Vif-mediated proteasomal deg-
radation, indicating that the domains of A3G involved in
binding to Vif (amino acids 126–132; [52,53] were not
misfolded. Third, the P22-H65R mutant of A3G exhibited
cytidine deaminase activity, indicating that this mutation
did not induce a conformational change in the C-terminal
CD2 domain. The retention of these biological activities
strongly argues that the CD1 domain mutations did not
result in the expression of misfolded proteins.
Virion incorporation of RNA-binding defective mutant A3G 
is restored upon fusion with non-specific RNA-binding 
peptide
Our studies showed that the H65R mutant of A3G was not
incorporated into virions. One study found that associa-
tion of A3G with 7SL RNA outside of the CD1 domain
was implicated in virion incorporation of A3G [54]. How-
ever, another study reported that downregulation of 7SL
RNA by overexpression of SRP19 did not influence A3G
encapsidation, suggesting that 7SL RNA binding is not
essential for A3G virion incorporation [55]. Other studies
have found that A3G interaction with viral genomic RNA
is essential for its virion encapsidation [56,57]. Our
results suggest that the CD1 domain mutation either
reduces A3G binding to viral or nonviral RNA [31], viral
genomic RNA [56,57], or 7SL RNA [54], resulting in
reduced virion incorporation. Analysis of the P22-H65R
mutant showed that addition of an RNA binding domain
to an RNA-binding defective mutant of A3G restored BiFC
and multimerization as well as virion incorporation, but
not antiviral activity. Additional studies of the P22-H65R
mutant and its ability to bind to viral genomic RNA and
7SL RNA may shed light on the A3G-RNA interactions
that play a critical role in A3G virion incorporation.
These results suggest that that multimers formed by an
intact CD1 binding to RNA are essential for inhibition of
viral replication. Multimers formed by the P22 peptide
binding to RNA were nonfunctional and were unable to
inhibit viral replication. Functional multimers formed by
an intact CD1 binding to RNA may be essential for the
previously reported processive movement on the sub-
strate DNA [58]. Another possibility is that the CD1 and a
properly formed multimer are required for A3G's incorpo-
ration into the virion core; thus, the P22-H65R multimers
may be packaged but may not be associated with the
reverse transcription complex in the virion cores. This
hypothesis is consistent with a recent report that a fusion
protein between the CD1 of A3G and APOBEC3A allowed
APOBEC3A to be associated with the nucleoprotein com-
plexes in the viral core; furthermore, the A3G-A3A fusion
protein inhibited viral replication [59]. Additional bio-
chemical studies are needed to determine why the P22-
H65R mutant is packaged but fails to inhibit HIV-1 repli-
cation.
Association of A3G with HIV-1 Gag is dependent on RNA 
binding
RNA-binding defective A3G mutants failed to reconstitute
BiFC with HIV-1 Gag constructs and an RNA-binding
defective HIV-1 Gag NC mutant also did not reconstitute
BiFC with wild-type A3G, suggesting that interaction
between Gag and A3G are mediated by an RNA bridge.Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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This observation is consistent with our previous results
that co-IP of Gag with A3G was abolished by treatment of
the cell lysate with RNase A [31]. However, additional
protein-protein interactions between A3G and HIV-1 Gag
upon binding to RNA cannot be excluded. Previous stud-
ies showed that the NC mutant pCCHH (C28H/H44C)
packaged very little HIV-1 RNA (<5%) and very low
amounts of non-specific RNA (~20%) [31,45]. In vitro
studies have suggested that mutations in the zinc finger
domains of NC have a lower affinity for RNA [45-48]. Our
studies suggest that the double mutant is severely defec-
tive in RNA binding, which results in the reduced packag-
ing of non-specific RNA [31].
The basic linker region of HIV-1 NC, and a peptide motif
at the C-terminal end of the NC domain of human T cell
leukemia virus type 1 (HTLV-1) have been implicated in
promoting and inhibiting virion incorporation of A3G,
respectively [35,60]. Our results suggest that an intact
structure of the HIV-1 NC zinc-binding domain influ-
ences RNA binding by HIV-1 Gag, which indirectly influ-
ences A3G virion incorporation.
The BiFC approach provides an alternative to the FRET
assay that was recently described [35]. In practice, the
BiFC assay is free from background fluorescence since the
NY and CY fragments of YFP do not fluoresce. On the
other hand, the FRET assay provides an ability to quantify
the efficiency of interactions between binding partners
[35]. These studies provide a powerful approach and
novel insights into the in vivo assembly of A3G multimers,
A3G-Gag interactions, and virion incorporation of A3G.
Conclusion
We have developed a robust BiFC assay to analyze intrac-
ellular A3G-A3G, A3G-Gag, and A3G-RNA interactions.
These studies show that A3G forms multimers in cells and
that this multimerization is dependent on RNA binding.
A heterologous RNA binding motif restored multimeriza-
tion but not antiviral activity, suggesting that formation of
functional multimers is dependent on an intact CD1 that
is capable of RNA binding. Finally, we observed weak
interactions between an A3G molecule with an intact CD1
and another A3G that is defective in RNA binding. The
weak interactions could explain previously described pro-
tein-protein interactions between purified A3G mole-
cules.
Methods
Plasmids and their construction
HIV-1-based vector pHDV-EGFP was kindly provided by
Derya Unutmaz (New York University) [61]; pHCMV-G
expresses the vesiculostomatitis virus envelope glycopro-
tein G from a human cytomegalovirus promoter [62]. pC-
HelpΔVif, kindly provided by Klaus Strebel (National
Institute of Allergy and Infectious Diseases, National Insti-
tutes of Health, Bethesda, MD), is a derivative of pC-Help;
it is an HIV-1 helper construct that lacks several cis-acting
elements needed for viral replication, including the pack-
aging signal and primer-binding site. pC-HelpΔVif
expresses all of the viral proteins except Vif, Nef, and Env
[63].
To generate A3G-NY and A3G-CY, A3G sequences were
amplified by PCR and replaced the gag sequences of pre-
viously described HIV-1-gag-NY and HIV-1-gag-CY [49].
The resulting plasmids were digested with NheI and BsiWI
and the 1773 and 1455 bp fragments containing A3G and
NY or CY, respectively, were cloned into the NheI and
Acc65I restriction sites of pCR 3.1 vector (Invitrogen) to
generate A3G-NY and A3G-CY. In these constructs, the
A3G and the NY (1–172 amino acids of YFP) or CY (173–
238 amino acids of YFP) sequences are separated by a 12
amino acid glycine-rich hinge sequence (PGISG-
GGGGILD) to provide flexibility to the fusion protein.
To generate NY-A3G and CY-A3G, NY and CY fragments
were amplified using HIV-1-gag-NY and HIV-1-gag-CY as
templates and subcloned into pcDNA-EYFP-A3G vector, a
derivative of pcDNA-APO3G. The NY and CY fragments
and A3G in the NY-A3G and CY-A3G constructs are sepa-
rated by a 19 amino acid glycine-rich flexible sequence
(EGITGGGGGILDGYLQNSR) to provide flexibility to
fusion proteins.
A3G BiFC constructs containing H65R, C97S, F70A,
Y91A, H257R, or C288S mutations were generated by the
QuikChange Mutagenesis Kit (Stratagene). The presence
of the desired mutations and the absence of inadvertant
mutations were verified by DNA sequencing.
P22-H65R-NY was constructed by inserting a synthetic
double-stranded DNA fragment encoding P22 peptide
into H65R-CY to generate P22-H65R-CY. The CY frag-
ment of P22-H65R-CY was replaced with the NY fragment
to generate P22-H65R-NY. The plasmids P22-A3G and
P22-H65R were constructed in a similar manner.
HIV-1-gag-NY and HIV-1-gag-CY plasmids have been
described previously [49]. Gag-NC* -NY was generated by
replacing the NC domain of the wild-type HIV-1 Gag with
NC zinc finger binding domain mutant CCHH/CCCC,
which contains C28H and H44C substitutions [45]. The
sequences and structures of all constructs were deter-
mined by DNA sequencing.
Transfections, infections, and flow cytometry analysis
Human 293T cells were maintained as described previ-
ously [31] and transfected by using a FuGENE 6 Transfec-
tion Reagent (Roche) or by the calcium phosphateRetrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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precipitation method [64]. Virus was harvested 48 hours
post-transfection, and the p24 capsid amounts in the cul-
ture supernatants were determined by ELISA (Perkin-
Elmer). The 293T cells were infected with virus prepara-
tions containing 100 ng of p24 capsid. The infected cells
were analyzed by flow cytometry (FACScan, Becton Dick-
inson) for green fluorescence 48 hours after infection, and
the results were analyzed with CELLQUEST software (Bec-
ton Dickinson). To determine the effects of A3G or A3G-
derived constructs on HIV-1 replication in the absence of
Vif, pHDV-EGFP, pC-HelpΔVif, pHCMV-G, and pcDNA-
A3G or A3G-derived constructs were co-transfected by
using 1:0.8: 0.25:0.25 μg of DNA per 35-mm-plate,
respectively. The molar ratios of pHDV-EGFP, pC-HelpΔ
Vif, pHCMV-G, and the pcDNA-A3G or A3G-derived con-
structs were approximately 1:1:0.4:0.4, respectively. Flow
cytometry analysis was also used to quantify YFP comple-
mentation from transiently transfected 293T cells.
Cytidine deamination assay and western blotting analysis
Total cellular protein extracts were prepared as described
[65], protein concentrations were determined using the
Bradford protein assay (Bio-Rad Laboratories), and 0.3 μg
of the protein was used to determine cytidine deamina-
tion activity using a previously described scintillation
proximity assay for cytidine deamination [31].
For Western blotting analysis, the 293T cells were co-
transfected with A3G-expressing plasmids and pC-HelpΔ
Vif or phVif. Approximately 48 hours after transfection, 2
× 106 cells were harvested, washed twice with ice-cold
phosphate-buffered saline (PBS), and lysed in 1 ml of
Complete M-Lysis Buffer in the presence of protease
inhibitor (Roche). Cell extracts were adjusted to equiva-
lent protein concentration, and equal aliquots were used
for western blotting analysis. A3G proteins were detected
by using ApoC17 rabbit anti-human A3G antiserum (a
kind gift from Klaus Strebel) or anti-c-Myc antibody pro-
duced in rabbit (Sigma-Aldrich). Vif proteins were
detected using a rabbit anti-Vif polyclonal antibody at a
1:5000 dilution [10], followed by an HRP-conjugated,
stabilized goat anti-rabbit secondary antibody (Pierce) at
a 1:10,000 dilution. The tubulin protein was detected by
using the anti-tubulin antibody (Sigma-Aldrich). Viral
like particles (VLPs) were produced from 293T cells trans-
fected with pHDV-EGFP, pC-HelpΔVif, pHCMV-G as well
as pcDNA-A3G, or A3G-derived constructs, or both HIV-1
and A3G-expressing plasmids by using a calcium phos-
phate precipitation method. VLPs were harvested 48
hours after transfection, filtered using 0.45-μm mem-
branes (Nalgene), and concentrated 20-fold by ultracen-
trifugation as described previously [10]. Viral lysates
containing 100 ng of p24 CA of 293T-derived HDV-GFP
Δvif virions were loaded per lane. HIV-1 Gag, Gag-NY,
Gag-CY, and Gag-NC*-NY proteins were detected using
human polyclonal HIV immunoglobulin (HIV-IG) antise-
rum (AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH).
Quantfication of the Western blots was performed using
the Odyssey software version 2.1 (Licor, Inc.). In addition,
SuperSignal West Femto Maximum secondary antibody
and Sensitivity Substrate (Pierce) was used in some West-
ern blotting experiments.
BiFC assay
The BiFC assay to examine the interactions were per-
formed by using an adaptation of a previously described
procedure [36,37]. HeLa cells were plated on glass bottom
No 1.5 uncoated γ-irradiated plates (MatTek Corp., Ash-
land, MA) 24 hours prior to transfection and maintained
in phenol-red free Dulbecco modified Eagles' medium
(Mediatch, Inc., Herndon, VA) supplemented with L-
glutamine and 10% fetal calf serum. HeLa cells were trans-
fected with 0.25 μg of A3G BiFC constructs per 35-mm
dish, unless stated otherwise; in experiments designed to
analyze interactions with HIV-1 Gag, 0.5 μg of A3G and
0.5 μg of HIV-1 Gag BiFC constructs were co-transfected
with 0.075 μg of mRFP1, unless stated otherwise. The
growth media was changed 6 hours before and after trans-
fection. Live cell imaging was performed at 37°C and 5%
CO2 after approximately 14 hours post-transfection using
Zeiss LSM510 META confocal fluorescence microscope
(Carl Zeiss) and 40× NA 1.3 oil immersion objective. A
488-nm argon laser with a 500- to 530-nm band-pass
emission filter and a 543-nm helium-neon laser with a
615- to 675-nm band-pass emission filter were used.
In order to quantify YFP fluorescence complementation,
293T cells were transfected with 0.25 μg of each BiFC con-
structs per 35-mm dish, and 0.15 μg mRFP1 plasmid was
co-transfected per transfection as an internal control. The
transfected cells were harvested approximately 14 hours
post-transfection. Cells were washed twice with 1 ml of fil-
tered 1× PBS, resuspended in 500 μl 1× filtered PBS, and
fixed with 100 μl of 6% paraformaldehyde for two hours.
The fixed cells were filtered using a 5 ml Polystrene round-
bottom tube with a cell-strainer cap (12 × 17 mm style;
BD Falcon) before flow cytometry analysis. The trans-
fected cells were analyzed by flow cytometry according to
the method described above. To quantify the amount of
complementation we analyzed both YFP and mRFP posi-
tive cells and determined the percentage of mRFP+ cells
that were YFP+.
Co-IP and protein visualization
293T cells were seeded at 4 × 106 cells per 100-mm dish
and were co-transfected 24 hours later using FuGene 6
Transfection Reagent (Roche) with 1 μg of each pF-A3G
and pcDNA3.1noMCS (empty vector), 1 μg each of pF-Retrovirology 2009, 6:56 http://www.retrovirology.com/content/6/1/56
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A3G and A3G-CY, 1 μg each of pF-A3G and P22-H65R or
P22-H65R-CY, or 1 μg of pF-A3G and 4 μg each of H65R-
CY or F70A-CY (Roche). The supernatant was removed 48
hours post-transfection, and the cells were washed twice
in 10 ml of phosphate buffered saline (PBS). The cells
were then lysed in 1 ml Complete M-Lysis Buffer in the
presence of protease inhibitor (Roche), by incubation
with gentle agitation for 15 min. The cellular debris was
removed by centrifugation at 10,000 × g for 10 minutes,
and the resulting supernatant was divided into two tubes
each contained 500 μl of the cell lysate. The lysate was
treated with 100 μg/ml RNase A or 80 U/μl of RNase
inhibitor (RNaseOUT; Invitrogen). These lysates were
incubated at 37°C for 1 hour. We then added to the cell
lysates 80 μl of 1× IP buffer (Sigma) and 20 μl of an anti-
FLAG M2 agarose affinity gel or anti-c-Myc affinity gel
(Sigma). The FLAG- or c-Myc-tagged A3G proteins were
allowed to bind to the agarose affinity gel by gentle rota-
tion at 4°C overnight, after which any unbound proteins
were removed by washing six times using 1× IP buffer and
a final wash with 0.1× IP buffer. The bound protein com-
plexes were then eluted using a 1× Laemmli sample buffer
(Sigma). The eluted complexes, as well as the input cell
lysates, were then analyzed by polyacrylamide gel electro-
phoresis and Western blotting. Untagged A3G and FLAG-
or c-Myc tagged A3G proteins were detected by using
ApoC17 rabbit anti-human A3G antiserum, a rabbit anti-
FLAG polyclonal antibody (Sigma), or a rabbit anti-c-Myc
monoclonal antibody (Sigma) at a 1:5,000 dilution, fol-
lowed by a HRP-labeled goat anti-rabbit secondary anti-
body (Sigma) at a 1:10,000 dilution. The proteins were
visualized using a Western Lighting Chemiluminescence
Reagent Plus kit (PerkinElmer).
Immunofluorescence staining of transfected cells
HeLa cells were plated on 15-mm-diameter coverslips (BD
Biosciences) for 24 hours prior to transfection. At 15
hours post-transfection, cells were fixed for 20 minutes at
room temperature in 5% paraformadehyde and 2%
sucrose in PBS, and permeabilized for 30 minutes with
1% Triton X-100 and 10% sucrose in PBS. Anti-A3G poly-
clonal antiserum was used as a primary antibody and
Alexa Fluor 488-conjugated goat antibody to rabbit IgG
(H+L) (Molecular Probes) as secondary antibody. Cells
were incubated sequentially with each antibody for 1
hour and washed three times. All washes and antibody
dilutions were performed in PBS containing 1% bovine
serum albumin (Sigma), 1% Triton X-100 (Sigma), and
2% normal goat serum (Vector Laboratories, Inc.).
Finally, the nuclei were stained by incubating the cells in
PBS containing 2 μg/ml of 4', 6-diamidino-2-phenyl-
indole (DAPI; Sigma) for 2 minutes followed by two
washes in PBS. The coverslips were rinsed in deionized
water and then mounted on glass slides by using Fluoro-
Guard (Bio-Rad). The cells were visualized using a
LSM510 Zeiss confocal fluorescence microscope (Carl
Zeiss).
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